Y-mAbs Therapeutics, Inc. (YMAB)

14.71 -0.13 (-0.88%) 收市：04:00PM EDT

Y-mAbs Therapeutics, Inc.

230 Park Avenue
Suite 3350
New York, NY 10169
United States
646 885 8505
https://www.ymabs.com

版塊: Healthcare
行業: Biotechnology
全職員工: 100

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Thomas Gad	Founder, Chief Business Officer & Vice Chairman	1.05M	無	1971
Mr. Bo Kruse	Executive VP, Secretary, Treasurer & CFO	685.02k	無	1973
Ms. Susan Smith	Senior VP & Chief Commercial Officer	710k	無	1971
Mr. Michael Rossi	CEO, President & Director	無	無	1971
Mr. Joris Wiel Jan Wilms	Senior VP & COO	無	無	1974
Dr. Torben Lund-Hansen M.Sc., Ph.D.	Senior VP & CTO	無	無	1951
Ms. Courtney Dugan	Vice President of Investor Relations	無	無	無
Dr. Vignesh Rajah M.B.A., MBBS	Senior VP & Chief Medical Officer	406.27k	無	1965

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Y-mAbs Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow. The company is also developing DANYELZA for the treatment of patients with second-line relapsed osteosarcoma and is in Phase II clinical study; GD2-SADA, which is in Phase I clinical trial for the treatment of GD2 positive solid tumor; and Omburtamab, a murine monoclonal antibody for the treatment of central nervous system/leptomeningeal metastases from neuroblastoma, as well as SADA PRIT technology platform. In addition, it is engages in the developing of CD38-SADA and GD2-GD3 Vaccine. The company has a license agreement with Memorial Sloan Kettering Cancer Center and Massachusetts Institute of Technology to develop and commercialize licensed products. Y-mAbs Therapeutics, Inc. was incorporated in 2015 and is headquartered in New York, New York.

公司管治

截至 2024年4月1日 止，Y-mAbs Therapeutics, Inc. 的 ISS 管治質素評分為 8。 Pillar 分數正在審核中：4；董事會：7；股東權利：8；現金賠償：9。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。